Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered ...

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

Recent internal guidance restricting the National Institutes of Health’s spending could affect researchers across the country, including those at Binghamton University. On Jan. 22, ...

Earlier this month, the Trump administration directed the National Institutes of Health (NIH) to impose limits on specific ...

The cuts hit the FDA’s medical device center particularly hard, impacting product reviewers and researchers of AI-enabled ...

Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs impacted by the uncertainty surrounding federal grants.

Chris Gibson, Recursion’s head, cited the role small business grants played in helping Recursion grow its business.

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...

These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.

As an organization founded with an SBIR NIH/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial ...

NIH announced it would limit indirect funding to 15% on Friday, but it is unclear how much money this will take from St. Jude ...